Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view.

- **TNBC, HGSOC, Endometrial, and advanced solid tumor with Tp53 mutation**
  - IRB 21548
    - A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors

- **Tumor Mutation Burden - High**
  - IRB# 18788
    - Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

- **NTRK, ROS1, ALK gene rearrangement**
  - IRB# 15206
    - Entrectinib in Patients with Advanced or Metastatic Solid Tumors (previously treated)
  - IRB# 17674
    - Loxo-195 in fusion-NTRK (previously treated) solid tumors

- **Fusion-NTRK (previously treated)**
  - IRB# 16676
    - BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

- **RET Mutations**
  - IRB# 18164
    - A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

- **Fusion Proteins Specific BRD Amplifications Specific MYC Amplifications Specific AR Amplifications Specific**
  - IRB# 16702
    - A Phase I/IIa Trial With BMS-986158 as Monotherapy or in Combination with Nivolumab in Subjects With Selected Advanced Solid Tumors

- **Tumor Mutation Burden - High**
  - IRB# 18788
    - Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

- **Folate Receptor Alpha Expression**
  - TNBC, NSCLC, EC, OC
  - IRB 21349
    - A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

- **Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway**
  - IRB 21819
    - A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

- **CLDN18.2 expressing solid tumors**
  - IRB 21819
    - A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

- **Key**
  - Open for Enrollment
  - In Development
  - Enrollment on Hold

3/16/2021

http://www.ohsu.edu/research/rda/so/knight.php
No known mutation, phase 1; TREM1 expression phase 2
Locally advanced or metastatic solid tumor with an NRG1 gene fusion
Solid Tumors likely to express ROR1
Solid Tumor likely responsive to immune checkpoint inhibitors and solid tumors with a KRASG12 mutation

P53 Y220C mutations
IRB 21998 coming soon
IRB 22223 coming soon
IRB 22580 coming soon
IRB 22680 coming soon
IRB 22798 coming soon